DF19001
Phase 1House-dust-mite allergy immunotherapy patch; Phase 1 was completed in December 2025 and a Phase 2b/3 trial application was filed in May 2026.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has allergy and obesity microneedle patches in clinical trials and signed a CDMO contract with a Japanese company for a sensor patch.
Roles often seen at this stageResearch & development · Clinical & PV · Manufacturing & MSAT
A drug-delivery company using dissolving microneedle patches to deliver drugs through the skin; its Cheonan plant holds MFDS pharmaceutical manufacturing approval.
House-dust-mite allergy immunotherapy patch; Phase 1 was completed in December 2025 and a Phase 2b/3 trial application was filed in May 2026.
Obesity patch developed with Daewon Pharmaceutical; in a Korean Phase 1 trial it showed about 30% relative bioavailability versus subcutaneous injection.
Handles formulation, process development and manufacturing of a microneedle biosensor patch for body-fat monitoring developed with Japan's Murata Manufacturing.
Signed a CDMO contract with Murata Manufacturing, through its Japanese subsidiary, to commercialize a microneedle sensor patch.
Filed a Phase 2b/3 trial application for the DF19001 allergy immunotherapy patch.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.